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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
Lurasidone is more safe and effective in the treatment of schizoaffective disorder and 
schizophrenia than other common anti-psychotic medications. 
 
Study Design: Review of two English language randomized double-blinded controlled 
comparisons and one English language Randomized open-label parallel-group 
comparison. 
 
Data Sources: The randomized double-blinded controlled comparison studies and the 
randomized open-label parallel-group comparison were all found using PubMed and 
EBSCOhost databases. All three articles were published in peer-reviewed journals. 
 
Outcomes Measured: Participant withdrawal due to adverse effects and treatment 
failure, patient responses to MATRICS consensus cognitive battery, interview responses, 
and patient responses on the schizophrenia cognition rating scale were all measured to 
determine the efficacy and safety of Lurasidone. 
 
Results: According to Harvey et. al, the difference between Lurasidone and other 
common anti-psychotics, such as Ziprasidone, is not statistically significant with a p= 
0.058. Potkin, et. al reported that Lurasidone is more safe and effective compared to other 
common anti-psychotics with a p= 0.020. McEvoy et. al demonstrated the safety and 
efficacy of lurasidone with p values <0.05. 
 
Conclusion: The results from this review are inconclusive. One study with a p value of 
0.020 and another with p values <0.05 indicates that Lurasidone is more safe and 
effective and, but a p value of 0.058 in the third study does not agree with the findings of 
the other studies. 
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Introduction 
 Schizophrenia and schizophrenic-type disorders are characterized by disturbances 
in mood, thought, behavior, and filtering of stimuli of any type.4  Schizophrenic patients 
on anti-psychotic medications experience a high prevalence of side effects, as high as 
86.19%, which can lead to non-adherence.6  This review evaluates two randomized 
control trials and a randomized open-label parallel group study to determine whether 
Lurasidone is more safe and effective than other, more commonly used anti-psychotic 
medications. 	   The average age of onset for men is early to mid-20’s and late-20’s for females.  
There is no way to predict the course of the disorder for each individual patient, but a 
decrease of symptoms over the course of the lifetime of a schizophrenic patient has been 
described in literature and is thought to be due to decreased dopamine activity as patients 
age.  There are both negative and positive symptoms associated with schizophrenia and 
schizophrenic-type disorders. Some negative symptoms are social withdrawal, anhedonia, 
avolition, and alogia.  Some positive symptoms are hallucinations, delusions, 
disorganized speech, and psychomotor abnormalities.  It is common for patients to 
experience both types of symptoms in the course of their life with schizophrenia.4 
Schizophrenia and schizophrenic-type disorders are not the most common 
psychological disorder encountered in medical practice, but the symptoms of this disorder 
can be very debilitating, resulting in a disruption of activities of daily living. The lifetime 
prevalence of schizophrenia in the general population is 0.3-0.7%, and that of 
schizoaffective disorder is 0.3%. 4  Patients with these types of disorders can be 
encountered in all settings of medicine, but particularly in Family Medicine and 
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Behavioral Medicine.  A 2004 study estimated that schizophrenic patients occupied one 
for every three psychiatric hospital beds in the United States that year. 5 The cost of care 
for these patients in 2004 was about $6.85 billion in both Canada and the U.S.  Due to the 
increase in morbidity and mortality, and decreased productivity associated with this 
disorder, about $4.83 billion is spent on healthcare-related issues, while the rest of the 
estimated expenditures come from non-healthcare related costs. 5  
These disorders are commonly treated with typical and atypical neuroleptics, as 
well as hospitalization.  Typical neuroleptics, such as phenothiazines, thioxanthenes, 
butyrophenones, dihydroindolones, dibenzoxazepines, and benzisoxazoles, are common 
neuroleptic anti-psychotics, which work on dopamine (D2) receptors.6  These typical anti-
psychotics treat only positive symptoms of schizophrenia, and are associated with 
increased extra-pyramidal symptoms with increasing doses.6  Atypical neuroleptics are 
clozapine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, paliperidone, 
iloperidone, and lurasidone. Atypical neuroleptics treat both the positive and negative 
symptoms of schizophrenia, and vary in their mechanism of action. Risperidone blocks 
D2 receptors and 5-HT2 receptors, and clozapine blocks D4 receptors, as well as sero 
tonergic, histaminergic, and alpha noradrenergic blocking capacities.6  Hospitalization is 
often needed when patient’s behaviors and delusions become harmful or dangerous to 
themselves or others. There is no cure for schizophrenia or schizophrenia-type disorders, 
but neuroleptics are effective in managing symptoms.  
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Objective  
The objective of this review is to determine whether or not lurasidone is more safe and 
effective in the treatment of schizoaffective disorder and schizophrenia than other 
common anti-psychotic medications.  
Methods 
The criteria for selection of the studies in this review were participants 18-years-old and 
older who have been diagnosed with either schizophrenia or schizoaffective disorder 
according to the DSM-V.  The participants in all of the studies selected took part in 
interventions involving lurasidone in various doses based on whether lurasidone is being 
compared to ziprasidone, or randomly assigned based on the patient’s use of sedating and 
non-sedating anti-psychotics previously.  
 PCOM library databases PubMed and Medline were used to find the data for this 
review. All of the data was published in English in peer-reviewed journals. Inclusion 
criteria included randomized control double-blind comparison studies, and a randomized 
open-label parallel-group study that reported patient-oriented outcomes. Exclusion 
criteria were patients younger than 18-years-old and research reporting non-patient 
reported outcomes.  Statistics reported in this review include p-values, NNH, ARI, and 
RRI. 
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Table 1. Demographics and Characteristics of included studies 
Study	   Type	   #	  Pts	   Age	  (yrs)	   Inclusion	  Criteria	   Exclusion	  Criteria	   W/D	   Interventions	  Harvey1(2011)	   Randomized	  double-­‐blind	  controlled	  comparison	  
301	   18-­‐70	  years	  old	   Community	  dwelling	  patients	  with	  schizophrenia	  or	  schizoaffective	  disorder	  who	  had	  never	  received	  treatment	  with	  Ziprasidone	  or	  Lurasidone	  
Patients	  younger	  than	  18,	  schizophrenia	  disorder	  that	  was	  chronic	  (at	  least	  6	  months)	  or	  has	  been	  hospitalized/	  experienced	  acute	  exacerbation	  of	  psychosis	  within	  last	  3	  months,	  history	  of	  head	  traum,	  substance	  abuse	  currently	  or	  in	  the	  past.	  
96	   Lurasidone	  120mg	  QD	  Ziprasidone	  80mg	  BID	  
McEvoy2	  	  (2013)	   Randomized	  Open-­‐label	  parallel-­‐group	  comparison	  
240	   18-­‐70	  years	  old	   Adults	  with	  DSM-­‐IV	  defined	  schizophrenia	  or	  schizoaffective	  disorder	  
Patients	  younger	  than	  18,	  in	  an	  acute	  phase	  of	  illness	  
19	   Lurasidone:	  40-­‐80mg/d	  over	  6	  weeks	  40-­‐120mg/d	  over	  6	  weeks	  	  	  
Potkin3	  (2011)	   Double-­‐blind	  Randomized	  control	  comparison	  	  
301	   18-­‐70	  years	  old	   Adults	  with	  schizophrenia	  or	  schizoaffective	  disorder	  that	  was	  chronic	  
Patients	  younger	  than	  18,	  patients	  who	  weren’t	  stable	  enough	  to	  be	  treated	  in	  outpatient	  setting	  
94	   Lurasidone	  120mg	  QD	  Ziprasidone	  80mg	  BID	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Outcomes Measured 
The outcomes measured in this review were withdrawal from the studies due to adverse 
effects, participant-based interviews and use of the Schizophrenia Cognition Rating 
Scale.  Investigators also used the MATRICS Consensus Cognitive Battery, Positive and 
Negative Syndrome Scale, Clinical Global Impressions-severity scale, and Calgary 
Depression Scale for Schizophrenia. 
Results 
McEvoy, et. al conducted a randomized, open-label parallel group study consisting of 
240 participants aged 18-72 who were diagnosed with schizophrenia or schizoaffective 
disorder and were not in an acute phase of the illness.  These participants were required 
to partake in a 14-day “wash-out” period, where they tapered their previous medications 
to 50% over the first 7 days, then tapered down to no medication by the 14th day.  The 
participants then started a 6 week period of lurasidone which started at 40 mg per day, the 
participants were then broken down into two groups based on whether they were on a 
sedating (olanzapine or quetiapine) or non-sedating medication (all others) prior to the 
start of the study.  The participants in each were randomly titrated up to either 80 mg or 
120 mg over 6 weeks.2  
 The two groups were 86 participants who were previously on sedating 
medications, and 154 were treated with non-sedating medications.  The study then 
measured time to treatment failure, which included failure of clinical response to 
lurasidone, discontinuation due to an adverse effect, or exacerbation of the disorder being 
treated. In the prior use of sedating medications group, 10 of the 86 participants withdrew 
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due to treatment failure, and 9 out of 154 of the other group withdrew for treatment 
failure.2 
 The effectiveness of lurasidone was measured using three scales valuing patient’s 
experience of symptoms.  The three scales were Positive and Negative Syndrome Scale, 
Clinical Global Impressions-Severity, and Calgary Depression Scale for Schizophrenia.  
Each participant’s change of score within each scale over 6 months was recorded, and the 
mean change and the p-value was recorded.   
Table 2. Results of McEvoy, et al randomized open-label parallel group study 
Rating Scale Mean Change p-value 
Positive and Negative 
Syndrome Scale 
-8.2 <0.0001 
Clinical Global Impressions-
Severity 
-0.39 <0.0001 
Calgary Depression Scale 
for Schizophrenia 
-1.2 0.0002 
 
 The results from this study demonstrate the efficacy of lurasidone in both groups.  
All three p-values indicate the overall changes in symptoms experienced by the 
participants in each group were statistically significant.  Thus, the changes the 
participants experienced were not due to chance, but due to the therapeutic effects of 
lurasidone. 
 Potkin, et. al studied 301 patients aged 18-70-years-old with schizophrenia or 
schizoaffective disorder in a 21-day randomized double-blind controlled comparison trial.  
The participants in this trial were randomly assigned to either lurasidone 120 mg every 
day (150 participants), or ziprasidone 80 mg twice per day (151 participants).  Among the 
301 participants, 94 withdrew from the study.  Of the 94 participants who withdrew, 
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32.5% (31 participants) of them were in the lurasidone treatment group and 30.7% (29 
participants) of them were from the ziprasidone treatment group.  Of those who withdrew 
in the lurasidone group, 10.4% (3 participants) were due to adverse effects of the 
medication compared to 11.1% (3 participants) in the ziprasidone group3.  
Table 3. Potkin et. al, double-blind controlled comparison trial 
Study Participants RRI ARI NNH p-value 
Potkin 301 -0.063 -0.7 -142 0.02 
 
Based on the participants who withdrew from the study, a relative risk increase value of   
-0.063 was determined, and an ARI of -0.7 was then calculated.  Number needed to harm 
in this study was -142, which implies that for every 142 patients exposed to lurasidone, 
one will discontinue it’s use due to adverse events.  The p-value of 0.02 signifies that this 
data is statistically significant, and that the results of this study did not happen due to 
chance (Table 3). 
The main adverse effects experienced in this study were insomnia, vomiting, 
nausea, headache, somnolence, anxiety, and sedation.  Of the 150 lurasidone participants, 
85 (56.7%) experienced one adverse effect.  Of these, 10 (6.7% of the total population) 
reported the adverse effect was severe.  In the ziprasidone group, 99 participants (65.6%) 
experienced an adverse effect, and 11 (7.3% of the total population) reported the adverse 
effects as severe.3 
 Harvey, et. al conducted a randomized double-blind controlled comparison trial 
comparing lurasidone 120 mg per day (150 participants) to ziprasidone 80 mg (151 
participants) twice per day in 301 participants diagnosed with schizophrenia or 
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schizoaffective disorder.  The participants were 18-70-years-old, who had not been 
hospitalized in the past 3 months for exacerbations of their schizophrenia or 
schizoaffective disorder.  At the end of the 21-day study, 67.5% of the lurasidone group 
and 69.3% of the ziprasidone group finished the treatments.  Using an interview-based 
cognitive function tool, Schizophrenia Cognition Rating Scale (SCoRS) and MATRICS 
Consensus Cognitive Battery (MCCB), efficacy of lurasidone was determined compared 
to ziprasidone.  Participants were evaluated at baseline as well as at week 3 with SCoRS, 
which included participant answers to interview questions and interviewer’s 
interpretation of the participant according to each question.  The overall change in 
SCoRS and MCCB ratings between the two groups was not statistically significant, but 
the change from baseline to week 3 in the lurasidone group proved to be statistically 
significant with a p-value of changes in MCCB scores of 0.026 and SCoRS of <0.001.  
Compared to the change in MCCB scores in the ziprasidone group p=0.254, and the 
SCoRS changes, p=0.158, which proved to not be statistically significant.  The difference 
between the scores in these two groups was found to not be statistically significant with 
p=0.058, indicating that the results found in this study could be attributed to chance.  As 
this data was not dichotomous, between group t-tests were performed by Harvey, et. al1.  
 Overall, this data shows that the change in schizophrenic and schizoaffective 
disorder patients experienced over the first three weeks was significant and not due to 
chance.  However, the p value between the lurasidone and ziprasidone groups was not 
statistically significant.  Therefore, there was no significant difference between the 
experimental and control groups. 
Discussion 
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Lurasidone was approved for use in treating schizophrenia and schizoaffective disorder in 
October, 2010.7  It is available for use in the United States for treatment of these 
disorders as well as bipolar disorder more commonly.  Lurasidone is a benzoisothiazol 
derivative and it’s mechanism of action is believed to be contributed to dopamine type 2 
(D2) and serotonin type 2 (5HT2A) receptor antagonism.  It is an oral medication that 
should start treatment at 40mg and titrated up to an appropriate dose for the patient, with 
80mg the suggested maximum dose.8  It is suggested by the manufacturers that lurasidone 
be taken with food, at least 350 calories.8 The cost of lurasidone can be a limiting factor 
for patients trying to receive treatment as the cost per unit is about $18.46/80mg and the 
cost for a 30-day supply for the maximum dose (80mg) is $603.60 without insurance.6   
 Lurasidone has two black box warnings associated with adverse effects in certain 
populations.  One of the black box warnings pertains to increase mortality risk due to 
cardiovascular or infectious events in patients using the medication for dementia-related 
psychosis.  The other black box warning is an increased risk of suicide in children, 
adolescents, and young adults with major depressive symptoms as well as psychotic 
symptoms.9   
 Some limitations encountered in searching for information for this review was the 
lack of studies that not only evaluated participants diagnosed with schizophrenia, but 
schizoaffective disorder as well.  While both disorders have similar symptoms, they are 
not identical and more information could have been gathered comparing more 
medications to lurasidone to determine true efficacy compared to other treatments.   
Conclusion 
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The results of the data in this review are inconclusive as to whether lurasidone is more 
safe and effective than other common anti-psychotic medications in the treatment of 
schizophrenia and schizoaffective disorder.  Many participants experienced adverse side 
effects in all of the experiments, but the number of participants who withdrew due to the 
severity of adverse effects varied.  In the study performed by McEvoy, et al demonstrated 
an improvement in the participant’s symptoms when switching from either non-sedating 
or sedating antipsychotics, supporting the idea that it is safe and effective to switch to 
lurasidone from other antipsychotics.  Harvey, et al showed that the changes experienced 
by the participants of that study were not statistically significant, so the decrease in 
symptoms in that study cannot be attributed solely to the medication.  More conclusive 
results could be attained if the studies used could have compared lurasidone to either 
atypical or typical anti-psychotics, so a distinct difference could be made between the two 
classes of anti-psychotics and lurasidone.  The results of this review could also be 
improved if a larger population was used, as the two randomized double blind controlled 
comparison studies contained the same number of participants and the same 
interventions, but were conducted by two different researchers.  These two studies could 
also be improved if they were to observe the participants on lurasidone for longer than 21 
days.  There were many factors that were not controlled in these studies, such as: diet, 
only comparing lurasidone to one other medication, and the medications the participants 
were on before starting the studies.  Diet could affect absorption of the drug and therefore 
the efficacy, and the lack of comparison of more medications in these studies made it 
impossible to compare the treatment of lurasidone with more than just ziprasidone.  The 
amount of time patients were off prior medications before starting the studies, as one of 
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the studies had a 14 day “wash-out” period, may not have been long enough for the 
medications to completely be out of the participants systems.  More research is necessary 
to determine a definitive answer to the objective of this review, and to provide more 
knowledge regarding the use of lurasidone in schizophrenia and schizoaffective disorder.   
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